TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3887499

Group type: EXPERIMENTAL
Intervention: Sensation information
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Self-instruction information
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Combined sensation and self-instruction information
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 31309643

Group type: EXPERIMENTAL
Intervention: 200 mg/day sesamin supplement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30355140

Group type: EXPERIMENTAL
Intervention: Target BP of ≈130/80 mm Hg in all hypertensive patients (based on HOT, ACCORD, SPS3 studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target BP of <140/90 mm Hg in most diabetes mellitus patients, <130/80 mm Hg in selected patients (American Diabetes Association guidelines)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achieving <140 mm Hg systolic BP
Number of subjects: 0
Study: 27461767

Group type: COMPARATOR
Intervention: TIVA0 (manual infusion guided by clinical signs)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: TIVABIS (BIS-guided infusion)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: TCI KBIS (BIS-guided target controlled infusion with Kataria model)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: TCI SBIS (BIS-guided target controlled infusion with Schnider model)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: TCI SBIS compared to TCI KBIS
Number of subjects: 66
Study: 24528939

Group type: EXPERIMENTAL
Intervention: HPLC diet (very low carbohydrate, 22 g/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: HPMC diet (moderate carbohydrate, 182 g/d)
Number of subjects: 12
Study: 22172502

Group type: EXPERIMENTAL
Intervention: Vero-derived vaccine
Number of subjects: 10460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10460

Group type: COMPARATOR
Intervention: Licensed egg-derived vaccine
Number of subjects: 10460
Study: 20048236

Group type: EXPERIMENTAL
Intervention: Prenatal and infancy nurse home visitation
Number of subjects: 310
Study: 16896735

Group type: EXPERIMENTAL
Intervention: 1-year strength training program for plantar-flexion (PF) muscles
Number of subjects: 23
Study: 16268973

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day and then 600 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12383542

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with biofeedback
Number of subjects: 94

Group type: COMPARATOR
Intervention: Pelvic floor muscle training without biofeedback
Number of subjects: 94
Study: 10402403

Group type: EXPERIMENTAL
Intervention: rec-FSH (Gonal-F, Serono) at a fixed dose of 150 IU/day for 3 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rec-FSH (150 IU/daily) continued until follicles were 10 mm in diameter, aspiration performed 72 h later
Number of subjects: 32

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 32
Study: 7554064

Group type: EXPERIMENTAL
Intervention: 300 g/day cooked Brussels sprouts
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucosinolates-free diet (control)
Number of subjects: 10
Study: 2376838

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anaerobic training
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 100
Study: 547122

Group type: EXPERIMENTAL
Intervention: Physostigmine (20 microgram/kg i.v.) with methylscopolamine (6 microgram/kg i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Scopolamine (6 microgram/kg i.v.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of scopolamine and physostigmine
Number of subjects: 6
Study: 29465293

Group type: EXPERIMENTAL
Intervention: Physical Activity Program (moderate intensity, 60 min/session, 3 sessions/week for 12 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no PA program, continued routine lifestyle)
Number of subjects: 75
Study: 28093928

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 21
Study: 26346300

Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg daily and doxycycline 100 mg daily
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg daily
Number of subjects: 292

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 292
Study: 23628835

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 100
Study: 21482570

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg administered intravenously every 12 h for 5-7 days
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g administered intravenously every 24 h for 5-7 days
Number of subjects: 1228
Study: 19346992

Group type: EXPERIMENTAL
Intervention: 8 KKW exercise
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: 12 KKW exercise
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: 4 KKW exercise
Number of subjects: 401

Group type: COMPARATOR
Intervention: Nonexercise (control)
Number of subjects: 401
Study: 16435344

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) with approximately 3,800 total shock waves, total energy delivery of 1,300 mJ/mm(2) in a single session
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 114
Study: 14755147

Group type: EXPERIMENTAL
Intervention: Procaine 2 g/24 h by continuous intravenous infusion
Number of subjects: 107

Group type: COMPARATOR
Intervention: Pentazocine 30 mg every 6 h as a bolus intravenous injection
Number of subjects: 107
Study: 11451725

Group type: EXPERIMENTAL
Intervention: Iron + folic acid + vitamin A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron + folic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin A
Number of subjects: 0
Study: 9736235

Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 89
Study: 8017359

Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 20

Group type: COMPARATOR
Intervention: Balloon feedback
Number of subjects: 20
Study: 2500139

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 50

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 50
Study: 5673964

Group type: EXPERIMENTAL
Intervention: Trimethoprim and sulphamethoxazole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 10
Study: 29608768

Group type: EXPERIMENTAL
Intervention: Crushed intranasal oxycodone ARIR
Number of subjects: 29
Study: 28391453

Group type: EXPERIMENTAL
Intervention: Theory of Mind (ToM) intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 136
Study: 24760534

Group type: EXPERIMENTAL
Intervention: 2.0g/d ginger
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ginger and Placebo
Number of subjects: 20
Study: 22531614

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training (30 Hz, 10 minutes, 3 times a week for 10 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no WBV training)
Number of subjects: 9
Study: 21307378

Group type: EXPERIMENTAL
Intervention: HbA(1c) levels 5.50-5.99%
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: HbA(1c) levels 6.00-6.49%
Number of subjects: 919

Group type: COMPARATOR
Intervention: HbA(1c) levels <5.0%
Number of subjects: 919

Group type: COMPARATOR
Intervention: HbA(1c) levels 5.00-5.49%
Number of subjects: 919
Study: 19332184

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Clopidogrel 300 mg loading dose
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Ticagrelor and Clopidogrel
Number of subjects: 18000
Study: 16984555

Group type: EXPERIMENTAL
Intervention: Y chromosome haplogroups
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 68
Study: 15198118

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (weekly for four weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional day care alone
Number of subjects: 46
Study: 11285662

Group type: EXPERIMENTAL
Intervention: Mass treatment of all children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted treatment of clinically active children and their household members
Number of subjects: 0
Study: 9253550

Group type: EXPERIMENTAL
Intervention: Chronic hypertension with superimposed preeclampsia (black women)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Chronic hypertension without preeclampsia (white women)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Chronic hypertension without preeclampsia (black women)
Number of subjects: 282
Study: 8390420

Group type: EXPERIMENTAL
Intervention: 63 Gy in 5 weeks (45 Gy 'large' field and 18 Gy 'boost')
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: 70.2 Gy in 5.5 weeks (50.4 Gy 'large' field and 19.8 Gy 'boost')
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: 70.2 Gy in 5 weeks (45 Gy 'large' field and 25.2 Gy 'boost')
Number of subjects: 355

Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 355
Study: 3425284

Group type: EXPERIMENTAL
Intervention: Immediate weight bearing
Number of subjects: 53

Group type: COMPARATOR
Intervention: Late weight bearing
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Evaluation radiographically and by roentgen stereophotogrammetric analysis
Number of subjects: 53
Study: 29607846

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Traditional Health Education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60
Study: 27766928

Group type: EXPERIMENTAL
Intervention: Average delta HR/BT with a cut-off ≥ 20
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Assumed delta HR/BT with a cut-off ≥ 5
Number of subjects: 124
Study: 24937345

Group type: EXPERIMENTAL
Intervention: Phenotype P (patients)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Phenotype H (hands)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Provider hands (referent)
Number of subjects: 170
Study: 22913430

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tryptophan-balanced control condition
Number of subjects: 20
Study: 22035502

Group type: EXPERIMENTAL
Intervention: Treatment in the patient's home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment in GP surgeries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital day unit (control arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All settings (home, GP surgeries, hospital)
Number of subjects: 0
Study: 18667247

Group type: EXPERIMENTAL
Intervention: Intensive Treatment (Atorvastatin 80 mg immediately after admission)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Treatment (Atorvastatin 20 mg from the day of discharge)
Number of subjects: 40
Study: 16556892

Group type: EXPERIMENTAL
Intervention: HDC/IL-2 treatment (10 cycles of IL-2 at 16,400 U/kg and HDC at 0.5 mg, administered subcutaneously twice daily)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 320
Study: 12875348

Group type: EXPERIMENTAL
Intervention: A-Cnotren/Pharmaten, Athens, Greece (test preparation)
Number of subjects: 38
Study: 14677622

Group type: EXPERIMENTAL
Intervention: gestodene 60 microg/ethinylestradiol 15 microg
Number of subjects: 124

Group type: COMPARATOR
Intervention: desogestrel 150 microg/ethinylestradiol 20 microg
Number of subjects: 124
Study: 8678384

Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges (13.3 mg of zinc from zinc gluconate, one lozenge every 2 hours while awake)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo lozenges (5% calcium lactate pentahydrate, one lozenge every 2 hours while awake)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 100
Study: 1840138

Group type: EXPERIMENTAL
Intervention: Paroxetine co-treatment for 16 days after a 7-day placebo treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paroxetine co-treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment for 7 days
Number of subjects: 20
Study: 6121568

Group type: EXPERIMENTAL
Intervention: Morphine sulphate 6 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methadone 6 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pethidine 60 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fentanyl 60 micrograms
Number of subjects: 24
Study: 30588680

Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 204

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 204
Study: 30506538

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound (IU)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Conventional group (laparoscopy only)
Number of subjects: 169
Study: 26860090

Group type: EXPERIMENTAL
Intervention: Open reduction and internal plate fixation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Closed reduction and plaster immobilisation
Number of subjects: 90
Study: 25153706

Group type: EXPERIMENTAL
Intervention: Community-based exercise programme (11 months, 3 times/week for 6 months, 2 times/week for 5 months)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Community-based exercise programme
Number of subjects: 159

Group type: COMPARATOR
Intervention: Self-management programme only (control)
Number of subjects: 159
Study: 22932743

Group type: EXPERIMENTAL
Intervention: Family Spirit intervention plus Optimized Standard Care
Number of subjects: 322

Group type: COMPARATOR
Intervention: Optimized Standard Care alone
Number of subjects: 322
Study: 20709137

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP10)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide (CP16)
Number of subjects: 92
Study: 17403074

Group type: EXPERIMENTAL
Intervention: PEG laxative (17 g daily)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: PEG treatment weeks
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo treatment weeks
Number of subjects: 304
Study: 11131817

Group type: EXPERIMENTAL
Intervention: Training with emotionally valenced (threatening) meanings of homographs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with threatening resolutions of ambiguous words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline condition (non-threatening resolutions)
Number of subjects: 0
Study: 9065963

Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 176

Group type: COMPARATOR
Intervention: Melperone
Number of subjects: 176
Study: 8417578

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supportive-expressive therapy (SET)
Number of subjects: 60
Study: 3757441

Group type: EXPERIMENTAL
Intervention: High calcium diet (1800 mg of calcium/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low calcium diet (200 mg of calcium/day)
Number of subjects: 8
Study: 30593111

Group type: EXPERIMENTAL
Intervention: Acid etching (40 s, 35% H3PO4) with glass ionomer cement (Ketac Molar Easymix)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No acid etching with glass ionomer cement (Ketac Molar Easymix)
Number of subjects: 100
Study: 26755409

Group type: EXPERIMENTAL
Intervention: 12-mm in-shoe orthotic heel lift
Number of subjects: 12
Study: 25724700

Group type: EXPERIMENTAL
Intervention: Curcumin (3 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23710881

Group type: EXPERIMENTAL
Intervention: P6 acupuncture bilaterally for 30 minutes, stimulated every 10 minutes to keep de qi sensation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture bilaterally for 30 minutes with no stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P6 stimulation via active TENS electrodes bilaterally for 30 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham P6 stimulation via inactive TENS electrode bilaterally for 30 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice of pharmacological emesis prevention (ondansetron 8 mg)
Number of subjects: 0
Study: 20470796

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) regimen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) regimen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 18241082

Group type: EXPERIMENTAL
Intervention: Adaptive design for dose-response trials
Number of subjects: 0
Study: 16637749

Group type: EXPERIMENTAL
Intervention: Threat-induced anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of behavioral inhibition
Number of subjects: 0
Study: 15030303

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary measures
Number of subjects: 0
Study: 10770216

Group type: EXPERIMENTAL
Intervention: rhIGF‐I (60 microg/kg, sc, twice daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: rhGH (12.5 microg/kg‐day, sc)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 8
Study: 8867568

Group type: EXPERIMENTAL
Intervention: Trandolapril (2-4 mg once-daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 1732769

Group type: EXPERIMENTAL
Intervention: High-osmolality contrast agent (Hypaque 76)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Low-osmolality contrast agent (Omnipaque 350)
Number of subjects: 505
Study: 29673832

Group type: EXPERIMENTAL
Intervention: PT using exergames
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PT using exergames combined with PS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PT using exergames combined with isoenergetic supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26940805

Group type: EXPERIMENTAL
Intervention: ABT-126 10 mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: ABT-126 25 mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: ABT-126 25 mg (nonsmokers)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 24290843

Group type: EXPERIMENTAL
Intervention: 5 μg Vi-CRM197
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Vi-CRM197
Number of subjects: 320
Study: 21852343

Group type: EXPERIMENTAL
Intervention: Family-based behavioral group intervention (Positively Fit; PF)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Brief family intervention (BFI)
Number of subjects: 93
Study: 20457644

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: bupropion sustained release
Number of subjects: 2045

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2045
Study: 17972024

Group type: EXPERIMENTAL
Intervention: EAP regimen (doxorubicin 40 mg/m², etoposide 360 mg/m², cisplatin 80 mg/m² every 28 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: HD 5-FU (5-FU 2.6 g/m² 24 h infusion, biweekly)
Number of subjects: 60
Study: 16898538

Group type: EXPERIMENTAL
Intervention: Selective alpha1-blocker (doxazosin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Behavioral therapy and rehabilitation
Number of subjects: 60
Study: 14653830

Group type: EXPERIMENTAL
Intervention: Metronidazole 250 mg t.d.s. for 10 days (Group A)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.d. for 10 days (Group B)
Number of subjects: 145
Study: 10794751

Group type: EXPERIMENTAL
Intervention: 2 mg of intravenous ibandronate
Number of subjects: 20
Study: 8799771

Group type: EXPERIMENTAL
Intervention: High intensity auditory stimuli (> 85 dB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental noises (e.g., baby's crying)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory stimulation of different intensities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of pleasant and unpleasant emotional reactions
Number of subjects: 0
Study: 1634646

Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nisoldipine 30 mg
Number of subjects: 48
Study: 6746177

Group type: EXPERIMENTAL
Intervention: 30‐s sprint bouts on a hydraulically braked Fitron ergometer
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 60‐s sprint bouts on a hydraulically braked Fitron ergometer
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Timed rides to exhaustion at 125% VO2max on an electrically braked Collins ergometer
Number of subjects: 27

Group type: COMPARATOR
Intervention: All tests
Number of subjects: 27
Study: 31673354

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub (ABHR) foam
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub (ABHR) gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both ABHR products
Number of subjects: 36
Study: 29893893

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 220

Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 220
Study: 26701117

Group type: EXPERIMENTAL
Intervention: P+HIIT (2 blocks per session of 3 different 15‐s plyometric exercises with 15‐s passive recoveries + HIIT program)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: P+HIIT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HIIT (2 blocks per session of 6‐8 bouts of 30‐s runs at 100% velocity at peak oxygen uptake)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 68